Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen Akcea Therapeutics.

In a Phase 2 research released in the NEJM in December 2014, individuals with FCS treated with volanesorsen accomplished substantial reductions in apoC-III, triglycerides, chylomicrons and apoC-III-associated very low density lipoprotein-cholesterol particles. Akcea is conducting an international multi-center currently, randomized, double-blind, placebo-controlled Stage 3 study in sufferers with FCS. Related StoriesBetalin launches new EMP technology that could transform diabetes treatmentResearchers reveal how billed gold nanoparticles influence framework of DNA and RNAMedUni Vienna researchers discover genetic cause of a rare disease FCS is definitely a rare and very serious genetic disorder connected with very high triglyceride levels that put patients vulnerable to possibly life-threatening pancreatitis.‘ This sustained actions of dopamine could be particularly important for understanding psychiatric conditions, which are characterized by persistently high degrees of the brain messenger, Beaulieu said. In the July 29 The researchers report their findings, 2005, issue of Cell. ‘This system is apparently more important than those earlier described for prolonged stimulation by dopamine, as would be the entire case in those with psychiatric conditions,’ said senior writer Marc Caron, Ph.D., of Duke.